Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
PureTech Health PLC (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PRTC
Nasdaq
8731
https://puretechhealth.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for PureTech Health PLC (ADR)
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
- May 9th, 2024 11:05 am
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
- May 7th, 2024 11:05 am
PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Call Transcript
- Apr 30th, 2024 12:37 pm
PureTech Announces Annual Results for Year Ended December 31, 2023
- Apr 25th, 2024 9:22 am
PureTech Health: Notice of Results
- Apr 18th, 2024 6:00 am
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
- Apr 16th, 2024 11:00 am
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
- Apr 11th, 2024 11:00 am
PureTech launches Seaport, hoping to create Karuna 2.0
- Apr 9th, 2024 12:19 pm
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
- Apr 9th, 2024 6:00 am
PureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable
- Apr 2nd, 2024 12:50 pm
PureTech Proposes $100 Million Capital Return
- Mar 19th, 2024 7:00 am
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
- Mar 18th, 2024 1:52 pm
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
- Mar 13th, 2024 11:00 am
PureTech to Present at Two Upcoming Investor Conferences
- Feb 27th, 2024 12:00 pm
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
- Feb 27th, 2024 7:00 am
Down -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a Turnaround
- Feb 15th, 2024 2:35 pm
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 12:00 pm
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
- Dec 22nd, 2023 2:13 pm
PureTech Year End Update and Outlook for 2024
- Dec 20th, 2023 7:00 am
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
- Dec 7th, 2023 11:00 am
Scroll